Company: ABBV
Filing Date: 2025-02-14
Form Type: 10-K
Source: 0001551152-25-000020
Chunk: 62

Company: AbbVie Inc.
Filing Date: 2025-02-14
Form: 10-K
Item: Item 3
Chunk 62
---
ATIONS

Net Revenues

The comparisons presented at constant currency rates reflect comparative local currency net revenues at the prior year's foreign exchange rates. This measure provides information on the change in net revenues assuming that foreign currency exchange rates had not changed between the prior and current periods. AbbVie believes that the non-GAAP measure of change in net revenues at constant currency rates, when used in conjunction with the GAAP measure of change in net revenues at actual currency rates, may provide a more complete understanding of the company's operations and can facilitate analysis of the company's results of operations, particularly in evaluating performance from one period to another.Percent changeAt actual currency ratesAt constant currency ratesyears ended (dollars in millions)2024202320222024202320242023United States$43,029 $41,883 $45,713 2.7 %(8.4)%2.7 %(8.4)%International13,305 12,435 12,341 7.0 %0.8 %11.1 %3.4 %Net revenues$56,334 $54,318 $58,054 3.7 %(6.4)%4.6 %(5.9)%

2024 Form 10-K   |  38

The following table details AbbVie's worldwide net revenues:Percent changeAt actual currency ratesAt constant currency ratesyears ended December 31 (dollars in millions)2024202320222024202320242023ImmunologyHumiraUnited States$7,142 $12,160 $18,619 (41.3)%(34.7)%(41.3)%(34.7)%International1,851 2,244 2,618 (17.5)%(14.3)%(13.2)%(11.8)%Total$8,993 $14,404 $21,237 (37.6)%(32.2)%(36.9)%(31.9)%SkyriziUnited States$10,086 $6,753 $4,484 49.3 %50.6 %49.3 %50.6 %International1,632 1,010 681 61.6 %48.3 %65.4 %50.3 %Total$11,718 $7,763 $5,165 50.